Neal Shore, MD, discusses the recent FDA approval of the first oral GNRH receptor antagonist, relugolix, for men with advanced prostate cancer, along with data from the phase 3 HERO trial.
Back
Post-Conference Perspectives: ASCO GU 2021
Post-Conference Perspectives: ASCO GU 2021
Episodes
All
All
Dan George, MD, reviews new findings in advanced prostate cancer presented at ASCO GU 2021.
Stephen Freedland, MD, discusses risk factors involved in men with advanced prostate cancer who receive androgen deprivation therapy.
Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
4
Dr Garg on a Phase 3 Study of Proton Therapy in Head and Neck Cancer
5